Genentech Oncology
This compound and its uses are investigational and have not been approved by the US Food and Drug Administration. Efficacy and safety have not been established. The information presented should not be construed as a recommendation for use. The relevance of findings in preclinical studies to humans is currently being evaluated.
The PI3K pathway is frequently dysregulated in HR+ breast cancer—promoting tumor growth, disease progression, and endocrine resistance. Dysregulation is typically caused by mutations in the genes coding for pathway enzymes, including PI3K. The PI3K family of proteins comprises a variety of isoforms, and mutations in the PI3Kα isoform gene—PIK3CA—have been implicated in HR+ breast cancer.1,4-10
Inavolisib is an investigational small molecule designed to selectively inhibit mutant PI3Kα. In preclinical models, this molecule showed potent selective inhibition of PI3Kα and has increased potency to mutant PI3K cells over wild type. It is less sensitive for the other three PI3K isoforms. Inavolisib binds to the ATP-binding site of PI3Kα, thereby blocking phosphorylation of PIP2 to PIP3 and preventing downstream signaling as shown in preclinical models. Moreover, inavolisib specifically degrades the mutant form of PI3Kα, resulting in reduction of pathway activity. The biochemical features of inavolisib are designed to optimize its cellular therapeutic index through reduced off-target cytotoxicity.
PIK3CA-mutant human breast cancer xenograft models demonstrated that the presence of inavolisib results in tumor regression, induction of apoptosis, and a reduction of pathway activity biomarkers (pAKT, pPRAS40, and pS6RP). Also, in a PIK3CA-mutant human breast cancer xenograft model, the combination of inavolisib with selective estrogen receptor degradation or CDK4/6 inhibition had synergistic antitumor activity.1,3
ATP=adenosine triphosphate; HR=hormone receptor; pAKT=phosphorylated AKT; PI3K=phosphatidylinositol 3-kinase; PIK3CA=phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha; PIP2=phosphatidylinositol 4,5-bisphosphate; PIP3=phosphatidylinositol 3,4,5-trisphosphate; pPRAS40=phosphorylated proline-rich AKT substrate of 40 kDa; pS6RP=phosphorylated S6 ribosomal protein.
Hong R, Edgar K, Song K, et al. Cancer Res. 2018;78:PD4-14.
Hong R, Edgar K, Song K, et al. Cancer Res. 2018;78:PD4-14.
Jones LH. Cell Chem Biol. 2018;25:30-35. PMID: 29174540
Jones LH. Cell Chem Biol. 2018;25:30-35. PMID: 29174540
Edgar K, Hanan E, Staben S, et al. Cancer Res. 2017;77:156.
Edgar K, Hanan E, Staben S, et al. Cancer Res. 2017;77:156.
LoRusso PM. J Clin Oncol. 2016;34:3803-3815. PMID: 27621407
LoRusso PM. J Clin Oncol. 2016;34:3803-3815. PMID: 27621407
Miller TW, Rexer BN, Garrett JT, Arteaga CL. Breast Cancer Res. 2011;13:224. PMID: 22114931
Miller TW, Rexer BN, Garrett JT, Arteaga CL. Breast Cancer Res. 2011;13:224. PMID: 22114931
Mukohara T. Breast Cancer (Dove Med Press). 2015;7:111-123. PMID: 26028978
Mukohara T. Breast Cancer (Dove Med Press). 2015;7:111-123. PMID: 26028978
Sabine VS, Crozier C, Brookes CL, et al. J Clin Oncol. 2014;32:2951-2958. PMID: 25071141
Sabine VS, Crozier C, Brookes CL, et al. J Clin Oncol. 2014;32:2951-2958. PMID: 25071141
Thorpe LM, Yuzugullu H, Zhao JJ. Nat Rev Cancer. 2015;15:7-24. PMID: 25533673
Thorpe LM, Yuzugullu H, Zhao JJ. Nat Rev Cancer. 2015;15:7-24. PMID: 25533673
Miller TW, Hennessy BT, Gonzalez-Angulo AM, et al. J Clin Invest. 2010;120:2406-2413. PMID: 20530877
Miller TW, Hennessy BT, Gonzalez-Angulo AM, et al. J Clin Invest. 2010;120:2406-2413. PMID: 20530877
Qin H, Liu L, Sun S, et al. PeerJ. 2018;6:e5092. PMID: 29942710
Qin H, Liu L, Sun S, et al. PeerJ. 2018;6:e5092. PMID: 29942710
Cintas C, Guillermet-Guibert J. Front Oncol. 2018;7:330. PMID: 29404273
Cintas C, Guillermet-Guibert J. Front Oncol. 2018;7:330. PMID: 29404273
The compounds and their uses mentioned on this website are investigational and have not been approved by the US Food and Drug Administration. Efficacy and safety have not been established. The information presented should not be construed as a recommendation for use. Do you wish to proceed?
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.